San Antonio Breast Cancer Symposium Posters2View(tm): Poster Number Index

Sponsored by

Poster Number Index

Click on one of the following number ranges below to display a list of posters. Click the checkbox next to each item to bookmark.
101 – 200 \| 201 – 300 \| 301 – 400 \| 401 – 500 \| 501 – 600 \| 601 – 700 \| 701 – 800 801 – 900 \| 901 – 1000 \| 1001 – 1100 \| 1101 – 1200 \| 2001 – 2100 \| 2101 – 2200 \| 3001 – 3100 3101 – 3200 \| 4001 – 4100 \| 4101 – 4200 \| 5001 – 5100 \| 5101 – 5200 \| 6001 – 6100 \| 6101 – 6152

[6102] Potential economic impact of the 21-gene recurrence score in Brazil.

[6103] Paravertebral block for breast surgery: a cost analysis.

[6104] Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

[6105] Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?

[6106] Modelling the cost-effectiveness of first, second and third generation polychemotherapy regimens in women with early breast cancer who have differing prognoses.

[6109] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) – a German health economic analysis.

[6110] Adjuvant chemotherapy in breast cancer: is TC a cost-effective regimen compared to AC?

[6111] Prospective cost analysis from the provider's perspective: pharmaco-economic results from AGO-WSG intergroup adjuvant EC→DOC trial vs. CMF in nodal-positive breast cancer and its reimbursement.

[6112] Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.

[6113] High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials.

[6114] Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.

[6115] Weekly paclitaxel versus weekly docetaxel in elderly and frail patients with metastatic breast carcinoma having failed previous anthracyclines: a randomised phase II study of the Belgian Society of Medical Oncology.

[6116] Randomized multicenter phase II trial of navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first line treatment in HER-2/neu negative metastatic breast cancer patients: updated results.

[6117] Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.

[6118] Phase II study of pegylated liposomal doxorubicin (PLD) and carboplatin (Cb) can be administered with trastuzumab (H) in patients with metastatic breast cancer.

[6119] Carmustine-methotrexate combination in breast cancer patients presenting with brain metastases.

[6120] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: phase II study.

[6121] A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study.

[6122] A multicenter phase II trial of weekly paclitaxel (wPC) and epirubicin (E) in first line metastatic breast cancer (MBC) and pronostic impact of VEGF level.

[6123] Efficacy of palliative chemotherapy for metastatic breast cancer according to HER2-status and basal cytokeratin expression.

[6125] All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

[6126] A comparison of high-dose (HD, 500 mg) fulvestrant vs anastrozole (1 mg) as first-line treatments for advanced breast cancer: results from FIRST.

[6127] Decreased expression of EZH2 is associated with ESR1 upregulation and response to anti-estrogens.

[6128] Combination of HDACi entinostat (SNDX-275) with letrozole provides control over tumor growth in MDA-MB-231 xenograft model.

[6129] High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “back to the future.”.

[6130] Fracture risk in women with breast cancer: can baseline assessment of risk be used to guide treatment?

[6131] Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.

[6132] Results of the German fulvestrant in practice evaluation programme to evaluate the efficacy, safety, tolerability and acceptance of fulvestrant under daily routine conditions.

[6133] Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.

[6134] Comparable efficacies between premenopausal and postmenopausal metastatic breast cancer patients by letrozole with and without goserelin as first line hormone therapy: a phase II parallel group study.

[6135] Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor.

[6136] Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab.

[6137] Venous thromboembolism (VTE) and erythropoiesis-stimulating agents (ESAs) in breast cancer: a single tertiary care center experience from the University of Arkansas for Medical Sciences (UAMS).

[6138] Interpreting the results of clinical trials of cancer chemotherapy: the importance of reporting concurrent supportive care.

[6139] First step in management of weight gain induced by chemotherapy for early breast cancer.

[6140] A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer.

[6141] The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor.

[6142] A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment.

[6143] Effect of glutamine on doxorubicin-induced cardiotoxicity: an echocardiographic assessment.

[6146] Expression of small sets of genes in carcinoma and stromal cells predict clinical behavior of human breast cancer.

[6147] Comparison of binary efficacy endpoints in 11 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials.

[6148] Fertility and pregnancy in patients below the age of 35 following chemotherapy for breast cancer.

[6149] Meta-analysis of adverse event rates in 15 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials for the development of adverse event stopping rules.

[6150] A comparative analysis of the attitudes of doctors and patients towards adherence behaviour and information provision.

[6152] Luminal group may give more benefit for invasive micropapillary carcinoma component breast cancer patients: experience from Cancer Hospital Fudan University.

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved